anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Autism spectrum disorder (ASD) diagnosis relies on clinical observation and documentation, but the presence of comorbidities can affect diagnostic validity across clinicians and exacerbate access to timely care. This study used latent class analysis to optimize subgroup identification based on functional level and associated comorbidities using the Behavior Assessment System for Children, Third Edition (BASC-3), and Vineland Adaptive Behavior Scales, Third Edition (Vineland-3), in a pediatric population referred for autism evaluation.
METHODS: This retrospective study reviewed clinical data extracted over a 3-year period (2018-2021). A latent class analysis was used to explore the presence of latent groups guided by the likelihood ratio test and fit indices. Additional analyses contrasted ASD and non-ASD groups on the BASC-3 and Vineland-3 variables.
RESULTS: There were 191 included participants (mean age 65.9 months, 76.4% male), of whom over half (60.7%) had an ASD diagnosis. Using 185 cases, the exploratory latent class analysis showed the emergence of 4 distinct subgroups. Composition of classes varied on ASD diagnosis, neurodevelopmental difficulties, behavioral health concerns, and intellectual disability. When contrasting ASD and non-ASD groups, significant between-group differences were observed across Vineland-3 variables and BASC-3 adaptive skills subscales indicating poorer social and adaptive functioning.
CONCLUSION: Latent class analysis of commonly used behavioral and adaptive measures can help distinguish between subgroups of pediatric patients referred for ASD evaluations and assist in triage of cases based on severity.
Each of the 22 volunteers will participate in a trial with both of the seat cushions. The test order is randomized.
PURPOSE:To make it possible to manufacture antigen which is specific to Treponema pallidum simply by immunizing an animal with the refined antigen obtained by refining the extract of Treponema pallidum, obtaining the antibody, making the antigen to be the fixed antibody, and bringing a sample containing the Treponema antigen into contact with the above described fixed antibody. CONSTITUTION:The extract of Treponema pallidum is coarsely manufactured by ion-exchange chromatography. Protein containing antigen is adsorbed by hydroxyapatite gel. Then, the adsorbed material is eluted, and the refined antigen is obtained. Thereafter, an animal is immunized with the refined antigen together with adjuvant. The animal which is utilized as an ordinary immunity animal such as a house rabbit and a rat can be used. The adjuvant is a material such as aluminum hydroxide having immunity activity action. The antibody which is obtained as antiserum or ascites is bonded to an insoluble carrier, and the fixed antibody is obtained. A sample containing TP antigen is brought into contact with the fixed antibody, and the TP specific antigen is adsorbed.
Because nicardipine hydrochloride capsules decrease peripheral resistance, careful monitoring of blood pressure during the initial administration and titration of nicardipine hydrochloride capsules are suggested. Nicardipine hydrochloride capsules like other calcium channel blockers, may occasionally produce symptomatic hypotension. Caution is advised to avoid systemic hypotension when administering the drug to patients who have sustained an acute cerebral infarction or hemorrhage. Because of prominent effects at the time of peak blood levels, initial titration should be performed with measurements of blood pressure at peak effect (1 to 2 hours after dosing) and just before the next dose.

Use in Patients With Impaired Hepatic Function: Since the liver is the major site of biotransformation and since nicardipine hydrochloride capsules are subject to first pass metabolism, the drug should be used with caution in patients having impaired liver function or reduced hepatic blood flow. Patients with severe liver disease developed elevated blood levels (fourfold increase in AUC) and prolonged half-life (19 hours) of nicardipine (see DOSAGE AND ADMINISTRATION).

Use in Patients With Impaired Renal Function: When nicardipine hydrochloride capsules 20 mg or 30 mg tid was given to hypertensive patients with mild renal impairment, mean plasma concentrations, AUC and C max were approximately twofold higher in renally impaired patients than in healthy controls. Doses in these patients must be adjusted (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).
Diabetic painful neuropathy a prevalent, disabling disorder. Currently, the only effective treatments are glucose control and pain management. Diabetic neuropathy is characterized by reduction of vascularity in peripheral nerves and deficiency in neurotrophic and angiogenic factors. Recent studies have shown that bone marrow (BM)-derived stem or progenitor cells have favorable effects on the repair of cardiovascular diseases. Since these BM-derived stem or progenitor cells contain various angiogenic and neurotrophic factors, these cells have been attempted for treating experimental diabetic neuropathy, and turned out to be effective for reversing various manifestations of experimental diabetic neuropathy.

However, stem-cell therapy was not proven in human study. Therefore, we will investigate the efficacy and safety of autologous peripheral blood stem cell injection in diabetic neuropathy.
This prospective randomized, single blind intervention study aims to proof a cognitive rehabilitation program for patients with mild dementia in Alzheimers Disease (AD). The investigators modified a manualized and established German behavioural therapy program (KORDIAL) to use in a group context. The respective modules contain multimodal and multiprofessional approaches to improve capabilities relevant to activities of daily living (external memory support, compensation strategies, training of everyday competence, communication training). The intervention group receives this therapy for 12 weeks. Age and gender matched participants with AD serve as active control sample receiving a standardized cognitive training in the domesticity. The primary outcome are measurements of skills in activities of daily living prior the intervention as well as at the end of the intervention (after 3 months) and after 6 months (Follow up).
ETHNOPHARMACOLOGICAL RELEVANCE: Shenling Baizhu San (SLBZS) is a formula of traditional Chinese medicine (TCM) that enhances the functions of the qi, spleen, and lung. According to the theory of TCM, chronic obstructive pulmonary disease (COPD) is often caused by lung qi deficiency, and SLBZS is often used in the treatment of COPD and has achieved remarkable results. However, the active components of SLBZS absorbed in serum and the underlying mechanism of SLBZS in treating COPD remain unclear and require further studies.
AIM OF THE STUDY: The objective of this study is to investigate the active components of SLBZS in rat serum, as well as the crucial targets and signaling pathways involved in the therapeutic effects of SLBZS for COPD.
MATERIALS AND METHODS: First, the absorption components and metabolites of SLBZS in rat serum were identified using ultra-performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS). Second, potential targets of SLBZS for the treatment of COPD were acquired from publicly accessible online sources. Cytoscape (v3.7.0) software was used to construct a component-target-pathway network and a protein-protein interaction (PPI) network. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of potential targets was performed using the Metascape database. The binding status of the active components in SLBZS to the potential targets was assessed with molecular docking technology. Finally, a cell model of COPD was successfully developed for experimental validation In vitro.
RESULTS: A total of 108 active components were identified, including 30 prototype components and 78 metabolites. A total of 292 potential targets for the treatment of COPD were identified, including TNF, IL-6, TLR9, RELA, and others. The KEGG pathway included inflammatory mediator regulation of TRP channels, necroptosis, and the NF-κB signaling pathway, among others. The In vitro experiments showed that SLBZS-containing serum had the ability to decrease the levels of inflammatory factors and cell death. Additionally, it was observed that SLBZS-containing serum could control the expression levels of TLR9, MyD88, TRAF6, NF-κB, and IκBα at the mRNA and protein levels. These findings suggested that SLBZS-containing serum was likely to be involved in the regulation of the TLR9/NF-κB pathway.
CONCLUSIONS: The mechanism of action of SLBZS on COPD was preliminarily elucidated using UPLC-Q-TOF-MS/MS, network pharmacology, and In vitro experiments. The primary active components and potential targets of SLBZS were identified, providing a scientific foundation for further research.
Complete Heart Block: Procainamide should not be administered to patients with complete heart block because of its effects in suppressing nodal or ventricular pacemakers and the hazard of asystole. It may be difficult to recognize complete heart block in patients with ventricular tachycardia, but if significant slowing of ventricular rate occurs during PA treatment without evidence of A-V conduction appearing, PA should be stopped. In cases of second degree A-V block or various types of hemiblock, PA should be avoided or discontinued because of the possibility of increased severity of block, unless the ventricular rate is controlled by an electrical pacemaker.  


Idiosyncratic Hypersensitivity: In patients sensitive to procaine or other ester-type local anesthetics, cross sensitivity to PA is unlikely. However, it should be borne in mind, and PA should not be used if it produces acute allergic dermatitis, asthma, or anaphylactic symptoms.  


Lupus Erythematosus: An established diagnosis of systemic lupus erythematosus is a contraindication to PA therapy, since aggravation of symptoms is highly likely.  


Torsades de Pointes: In the unusual ventricular arrhythmia called “les torsades de pointes” (twistings of the points), characterized by alternation of one or more ventricular premature beats in the directions of the QRS complexes on ECG in persons with prolonged Q-T and often enhanced U waves, Group 1A antiarrhythmic drugs are contraindicated. Administration of PA in such cases may aggravate this special type of ventricular extrasystole or tachycardia instead of suppressing it.
Invasive extraintestinal pathogenic Escherichia coli disease (IED) is defined as an acute illness consistent with systemic bacterial infection, which is microbiologically confirmed either by the isolation and identification of Escherichia coli (E. coli) from blood or any other sterile body sites, or by the isolation and identification of E. coli from urine in a participant with urosepsis and no other identifiable source of infection. ExPEC9V (JNJ-78901563, primary compound number: VAC52416) is a 9-valent vaccine candidate in development for active immunization for the prevention of IED in adults 60 years of age and older. Although IED affects all ages, adults aged greater than or equal to (\>=) 60 years have an increased risk of developing IED, including bacteremia and sepsis, which can be community-acquired, hospital-acquired or healthcare associated. As the mechanism of action of conjugate vaccines in the prevention of invasive disease is not expected to be affected by antibiotic resistance mechanisms, that is, resistance mechanisms are not linked to O-polysaccharide structures, the sponsor has no reason to expect a difference in outcome of efficacy between antimicrobial-resistant and susceptible O-serotypes. This study incorporates an inferentially seamless group-sequential design. This study consists of a Screening Phase (selected screening procedures may be performed up to 8 days prior to vaccination on Day 1), Randomization, Vaccination Phase (Day 1) and Follow-up Phase (up to 4 years post-vaccination). The total study duration is approximately up to 6 years 9 months. Key safety assessments include serious adverse events (SAEs), solicited and unsolicited adverse events (AEs), physical examination, and vital signs.
Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.
Patients randomized to the "Treat-to-target" group is prescribed with a systematic prednisolone taper according to a specific scheme. The starting dose can be increased if remission is not reached initially or in case of relapse, folloved by taper according to the specific scheme. A nurse will make a minimum of 5 phone consultations the first year, and hereafter minimum every 3 months.
Arrhythmia is the main cause of sudden cardiac death, and ECG signal analysis is a common method for the noninvasive diagnosis of arrhythmia. In this paper, we propose an arrhythmia classification model based on the combination of a channel attention mechanism (SE module), convolutional neural network (CNN), and long short-term memory neural network (LSTM). The data of this model use the MIT-BIH arrhythmia database, and after noise reduction of raw ECG data by the EEMD denoising algorithm, a CNN-LSTM is used to learn features from the data, and the fusion channel attention mechanism is used to adjust the weight of the feature map. The CNN-LSTM-SE model is compared with the LSTM, CNN-LSTM, and LSTM-attention models, and the models are evaluated using Precision, Recall, and F1-Score. The classification performance of the tested CNN-LSTM-SE classification prediction model is better, with a classification accuracy of 98.5%, a classification precision rate of more than 97% for each label, a recall rate of more than 98%, and an F1-score of more than 0.98. It meets the requirements of arrhythmia classification prediction and has a certain practical value.
BACKGROUND: Anastomotic leakage is one of the most severe adverse events of minimally invasive esophagectomy for esophageal cancer. Early postoperative endoscopy is considered to be the most objective means to diagnose anastomotic leakage, but its safety is questioned by clinicians. This study aimed to evaluate the safety and effectiveness of early postoperative endoscopy in predicting anastomotic leakage.
METHODS: Patients who underwent minimally invasive esophagectomy (from January 2017 to June 2021) in our center were identified and divided into early postoperative endoscopy and control groups according to whether they underwent early postoperative endoscopy within 72 hours after surgery. Propensity score matching was used to balance baseline characteristics. The incidence of postoperative adverse events was compared between the 2 groups, risk variables for anastomotic leakage were identified using logistic regression, and abnormal endoscopic findings related to anastomotic leakage occurrence were explored.
RESULTS: A total of 436 patients were enrolled, of whom 134 underwent early postoperative endoscopy. One hundred and thirty-two pairs were matched by propensity score matching, and baseline characteristics were well-balanced. Both before and after propensity score matching, early postoperative endoscopy did not increase the incidence of postoperative adverse events (chyle leak, hypoproteinemia, pneumonia, etc) and in-hospital mortality. Notably, the incidence of anastomotic leakage (9.8% vs 22.7%) and the length of mean postoperative hospital stay (17.6 vs 20.9 days) was significantly decreased in the early postoperative endoscopy group. Finally, based on the findings under early postoperative endoscopy, we found that gastric graft ischemia is related to a higher incidence of anastomotic leakage (P = .023).
CONCLUSION: Early postoperative endoscopy does not increase postoperative adverse events after minimally invasive esophagectomy and may guide early prediction and intervention strategies for anastomotic leakage in patients undergoing minimally invasive esophagectomy.
The present invention relates to a novel Enterobacter sp. strain SSYL deposited under accession number KCTC 0687BP isolated from the root bark of Chinese elm, which produces immunostimulating exopolysaccharides with anticancer activity, a process for preparing the exopolysaccharides by fermenting the said microorganism in a culture medium, exopolysaccharides prepared by the process and their uses thereof. The exopolysaccharides of the invention have a molecular weight of 100,000 to 1,000,000 and consist of 40-75% of total sugar, 5-15% of total acidic sugar and 10-25% of total protein. The exopolysaccharides exhibits a high immunoenhancing activity in immune cell proliferation, direct mitogenicity and mixed lymphocyte reaction, and further a high anticancer activity in vivo by virtue of immunostimulation. Moreover, the production of the exopolysaccharides by fermentation of a microorganism, makes it possible to provide the exopolysaccharides with a uniform quality and mass production without destruction of the plant species. The exopolysaccharides of the subject invention have practical uses as an active ingredient for anticancer agents, immunoenhancers and foodstuffs.
NEW MATERIAL:A compound expressed by the formula R1 is H or lower alkyl; R2 is [lower haloalkyl, lower alkoxycarbonyl, carboxyl or (lower alkyl- substituted)amino]phenyl, furil, thienyl or pyridinyl. EXAMPLE:5-[2-(4-trifluoromethylphenyl)ethenyl]-1,2-dithiol-3-thione]. USE:Physic. Active ingredient of immunomodulator. Useful for remedy of autoimmune disease such as chronic associated rheumatis, systematic lupus erythematosus, nephritis and multiple sclerosis, and other immediate and delayed allergy, malignant tumor, grave infections disease, immunodeficiency disease, immune depression disease, etc. PREPARATION:For instance, 5-methyl-1,2-dithiol-3-thione derivative and alpha,alpha,alpha- trifluoro-p-tolaldehyde are heated and refluxed in a solvent such as methanol and in the presence of base such as piperidine to obtain a compound expressed by the formula.
The invention discloses a joint MRI image recognition method and system based on artificial intelligence, comprising the following steps: firstly, inputting the acquired joint MRI image into a pre-trained interference elimination model, and eliminating noise and interference. And then determining the lesion type corresponding to the image to be analyzed by using a deep learning technology. And then, extracting corresponding recommended drugs from a preset drug database according to the identified lesion types. The drug database is established by medical specialists and contains various lesion types and corresponding drug information. And finally, taking the identified lesion type and the recommended medicine as output results. By the design, lesions in the joint MRI image can be automatically identified, corresponding medicines are recommended according to the identification result, diagnosis efficiency and accuracy are improved, and individuation and accurate treatment scheme formulation are facilitated.
Patients included in the control group before intervention will receive the usual practices. As part of the study, they will be contacted for data collection 6 months after the transition to home by a clinical research associate.
There are limitations in our routine standard of practice in Emergency medical clinic in rapid triage about the adequacy particularly in the patient group where specific and rapid decision-making, such as trauma. The process of evaluating the patients who are directed to the green area unnecessarily in trauma care by the physician is prolonged, the evaluation process of patients who are directed to the red area unnecessarily shortens but hospital resources are being used extensively. Therefore, in this study, it was planned to perform objective triage with a computer based scoring system. Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (EMT), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded. To the other group, triage maintenance / evaluation will be done with computer software developed by us. All patients with trauma should be included in the study, demographic data, trauma mechanism and trauma type vital signs at the time of application of the patients will be routinely observed in both groups of patients. These observations are routine for this disease group and we will not undertake any interventional procedures or screening except special routine application for research purposes. The observation and file information will be organized by the triage staff in both groups at the time of the application of the patients. In this software-based program before working on the software informative training will be given to triage staff and for this patient triage handheld computers will be given to triage staff. In order for the referring patients to be able to see the entries made with the triage software a simultaneous large-screen monitor will be used. At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
Anti PD1 inhibitor (Pembrolizumab, Nivolumab) is approved for recurrent/metastatic HNCC. However, response rates to Pembrolizumab or Nivolumab monotherapy are as low as 16-19%, underscoring the presence of immune evasion mechanisms. One of the main immune escape mechanisms described in HNSCC is poor tumor microenvironment characterized by defective HLA class I processing and antigen presentation, which allows tumor cells to evade their detection and destruction by cytotoxic CD8+ T-cells. Mutations or downregulation of the expression of HLA class I component including beta-2- microglobulin (β2M) and antigen processing machinery (APM) genes have been correlated with poor prognosis of HNSCC. Recent studies showed that de novo DNA methylation programs renders terminal T cell exhaustion and subsequent exhausted T cells are refractory to PD-1 blockade mediated rejuvenation. Pretreatment with DNA methyltransferases (DNMT) inhibitor prior to PD-L1 blockade showed enhancement of T cell responses and tumor control during PD-1 inhibitors in mice. A pilot study of novel combination of antiPD-1 and decitabine was conducted in patients with refractory or recurrent AML. The showed a best response of stable disease or better in 6 of 10 patients in patients with R-AML. A phase II clinical trial of anti-PD-1 camrelizumab plus decitabine, in relapsed/refractory Hodgkin lymphoma showed CR rate of 79% with decitabine plus camrelizumab compared to 32% with camrelizumab alone. Based on the promising results of decitabine enhances immune response and antitumor activity shown in both preclinical and preliminary clinical data from the phase II trial of hematological malignancies, I hypothesize that ASTX727 (oral decitabine and cedazuridine) changes DNA methylation status which may enhance the antitumor immune response by modulating tumor immune microenvironment and promoting increased tumor-infiltrating lymphocytes, which may enhance response to anti-PD1 inhibitor in R/M HNSCC patients
This cohort consists of 600 radiographs collected from pediatric and adult patients, aged 1 to 99 years, who underwent X-ray imaging for musculoskeletal conditions. The radiographs include various body parts such as the foot, ankle, knee, hand, wrist, elbow, shoulder, and pelvis. Fractures were present in 95 cases, while 453 cases showed no fractures.